Back
ESC Professional Premium Access

SGLT2 inhibitors should be first-line treatment in HFrEF: con

Session: Great Debate: controversies in the contemporary management of HFrEF
Topic: Cardiovascular Pharmacotherapy
Speaker: Professor J. Cleland (Glasgow, GB)
Event: ESC Congress 2023

Congress Presentation

About the speaker

Professor John Cleland

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
82 presentations
10 followers

5 more presentations in this session

SGLT2 inhibitors should be first-line treatment in HFrEF: pro

Speaker: Professor M. Packer (Dallas, US)

Access
Slides
Video
Thumbnail

SGLT2 inhibitors should be first-line treatment in HFrEF - discussion

Access
Video
Thumbnail

There is a role for anticoagulation in patients with HFrEF in sinus rhythm: pro

Speaker: Associate Professor F. Marin (Murcia, ES)

Access
Slides
Video
Thumbnail

There is a role for anticoagulation in patients with HFrEF in sinus rhythm: con

Speaker: Doctor C. Reddin (Galway, IE)

Access
Slides
Video
Thumbnail

There is a role for anticoagulation in patients with HFrEF in sinus rhythm - discussion

Access
Video
Thumbnail

Access the full session

Great Debate: controversies in the contemporary management of HFrEF

Speakers: Professor J. Cleland, Professor M. Packer, Associate Professor F. Marin, Doctor C. Reddin
Access
Video
Thumbnail

About the event

Image

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb